Live Chat ×
Skip to main content

CME/CE Monograph

To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.

FORMAT: Monograph - Please click here to view the monograph. 

November 18, 2020

MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™, 1.5 contact hours, and 1.5 ACHE Qualified Education Hours

For CME Credits (Physicians), Click Here

For ACPE Credits, Click Here

For ACHE Credits,
Click Here

For all other users, Click Here

Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss among older people in the United States. Its treatment has been revolutionized by anti–vascular endothelial growth factor therapy, but achieving optimal outcomes for individual patients depends on timely initiation of effective therapy and careful follow-up with ongoing treatment to control disease activity. Individualization of treatment plans is a key theme for achieving good outcomes. In real-word settings, however, there are challenges to meeting these needs. Collaboration between payers and providers is critical for enabling selection of the most appropriate treatment for patients with nAMD and improving overall visual outcomes. It is important that retinal specialists understand the issues payers face in their efforts to balance cost, quality, and access on a population-wide basis. At the same time, there is a need for payers to understand the issues confronting retinal specialists as they try to preserve vision and quality of life of patients with nAMD. Payers must also understand the current landscape of nAMD treatment and the evidence on which it is based so that best clinical practices are incorporated into payer models for covering care.


Target Audience
This activity is intended for managed care clinical and nonclinical executives engaged in the care of patients with nAMD.

Educational Objectives
After completing this activity, the participant should be better able to:
• Explain current practice patterns for the treatment of patients with nAMD
• Outline the benefits of collaboration between payers and providers

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing

Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education
(Universal Activity Number - JA4008162-9999-18-408-H01-P)

Type of Activity:

ACHE Qualified Education
By attending the Understanding the Treatment Paradigm for Age-Related Macular Degeneration offered by Postgraduate Institute for Medicine, participants may earn up to 1.5 ACHE Qualified Education Hours toward initial certification or recertification of the Fellow of the American College of Healthcare Executives (FACHE) designation.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

W. Lloyd Clark, MD
Consulting fees from Genentech, Inc; and Regeneron Pharmaceuticals, Inc

Fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speakers’ bureaus) from Genentech, Inc; and Regeneron Pharmaceuticals, Inc

Contracted research from Genentech, Inc; and Regeneron Pharmaceuticals, Inc

Jeffrey S. Heier, MD

Consulting fees from Adverum; Apellis Pharmaceuticals; Bayer Corporation; Chengdu Kanghong Pharmaceutical Group Co, Ltd; Daiichi Sankyo Company, Limited; F. Hoffman-La Roche Ltd; Genentech, Inc; Hemera Biosciences; Notal Vision; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; SciFluor Life Sciences, Inc; Stealth BioTherapeutics Inc; and Tyrogenex

Contracted research from Aerpio Therapeutics; Apellis Pharmaceuticals; Corcept Therapeutics; Daiichi Sankyo Company, Limited; F. Hoffman-La Roche Ltd; Genentech, Inc; Genzyme Corporation; Hemera Biosciences; Janssen Global Services, LLC; Ophthotech Corporation; Optovue, Incorporated; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; SciFluor Life Sciences, Inc; and Tyrogenex

Ownership interest in Ocular Therapeutix, Inc

Gary Owens, MD

Dr Owens has nothing to disclose.

Winston Wong, PharmD

Dr Wong has nothing to disclose.

Peer Reviewer
Jordana G. Fein, MD, MS,
has no relevant commercial relationships to disclose.

Planners and Managers

The PIM planners and managers have nothing to disclose. The MedEdicus planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period November 1, 2018, through November 30, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media Monograph Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

This CME/CE activity is copyrighted to MedEdicus LLC ©2018. All rights reserved. 159

CME/CE Monograph